Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Clinical Experience with Telavancin: Real-World Results from the Telavancin Observational Use Registry (TOURâ„¢).

Bressler AM, Hassoun AA, Saravolatz LD, Ravenna V, Barnes CN, Castaneda-Ruiz B.

Drugs Real World Outcomes. 2019 Nov 6. doi: 10.1007/s40801-019-00165-8. [Epub ahead of print]

PMID:
31696440
2.

Telavancin in Hospital-Acquired and Ventilator-Associated Pneumonia (HAP/VAP) Caused by Staphylococcus aureus: Post Hoc Analysis of 2 Randomized, Controlled Trials.

Niederman MS, Lee PC, Barriere SL, Barnes CN, Castaneda-Ruiz B.

Infect Dis Ther. 2019 Sep;8(3):445-452. doi: 10.1007/s40121-019-0255-0. Epub 2019 Aug 1.

3.

Considerations for Clinical Trials of Staphylococcus aureus Bloodstream Infection in Adults.

Holland TL, Chambers HF, Boucher HW, Corey GR, Coleman R, Castaneda-Ruiz B, Fowler VG.

Clin Infect Dis. 2019 Feb 15;68(5):865-872. doi: 10.1093/cid/ciy774.

4.

Telavancin in the Treatment of Concurrent Staphylococcus aureus Bacteremia: A Retrospective Analysis of ATLAS and ATTAIN Studies.

Wilson SE, Graham DR, Wang W, Bruss JB, Castaneda-Ruiz B.

Infect Dis Ther. 2017 Sep;6(3):413-422. doi: 10.1007/s40121-017-0162-1. Epub 2017 Jul 10.

5.

Safety and Tolerability of Doripenem in Hospitalized Children With Complicated Intra-Abdominal Infection, Complicated Urinary Tract Infections and Pneumonia.

Cannavino CR, Castaneda-Ruiz B, Redman R, Go O, Cirillo I, Barauskas V, Senatorova G, Emeryk A, Bradley JS.

Pediatr Infect Dis J. 2015 Nov;34(11):1264-7. doi: 10.1097/INF.0000000000000859.

PMID:
26226440
6.

Open-Label Study To Evaluate the Single-Dose Pharmacokinetics, Safety, and Tolerability of Doripenem in Infants Less than 12 Weeks in Chronological Age.

Cirillo I, Vaccaro N, Castaneda-Ruiz B, Redman R, Cossey V, Bradley JS, Allegaert K.

Antimicrob Agents Chemother. 2015 Aug;59(8):4742-9. doi: 10.1128/AAC.00485-15. Epub 2015 May 26.

Supplemental Content

Loading ...
Support Center